ÐÂÔÂÖ±²¥

 Published: 11 Sep 2020 | Last Updated: 28 Sep 2020 11:27:50

Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the ÐÂÔÂÖ±²¥ (RVC) has today presented a poster at the American Society of Bone and Mineral Research (ASBMR) highlighting a potential new treatment for skeletal disorders such as osteoporosis.

Osteoporosis affects over 3 million people in the UK and more than 500,000 people receive hospital treatment for bones that break after falling from standing height or less every year due to the condition. 

The condition also creates a significant social and economic burden, with fractures often leading to a downward spiral of disability, loss of independence and increased mortality.

In previous studies, NaQuinate, a naphthoquinone carboxylic acid which naturally occurs as a metabolite of vitamin K, has been shown to protect against the reduction in bone quality and quantity that occurs in response to ovariectomy in rat and mouse models. But in this new study, developed in collaboration between the Skeletal Biology group at the RVC and biotechnology company Haoma Medica, NaQuinate was also shown to significantly synergise with mechanical loading in targeted cortical bone regions. 

Female 12-week old mice were randomly assigned to two groups, receiving either NaQuinate or vehicle five days per week over a period of three weeks. On three alternate days in the final two weeks, the right tibia of each mouse was non-invasively subjected to dynamic axial loading with the left serving as non-loaded contralateral control.

This synergistic interaction between NaQuinate and mechanical loading indicates functional utilisation of bones’ mechanostat, a term describing the way in which mechanical loading influences bone structure, in the regulation of bone mass and architecture, thus supporting the notion that NaQuinate treatment can provide a novel therapeutic approach to skeletal disorders like osteoporosis in humans.

NaQuinate as a treatment for post-menopausal women with osteoporosis is an investigational product, currently in Phase I clinical trials to establish its safety and efficacy.

Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the ÐÂÔÂÖ±²¥, said: “There are three main ways to maintain bone quality and strength to resist fracture: stop bone loss, build mass and enhance the topographical changes to optimise and enhance weight-bearing roles. It may be that NaQuinate can achieve a balance of all three to treat osteoporosis and better maintain healthy ageing.

“I would like to thank my colleagues at the Skeletal Biology Group at the RVC, and the team at Haoma Medical for their support in this important study. At the RVC we recognise the importance of a collaborative ‘One Health’ approach which operates at the cutting edge of veterinary and human medicine, and this research could pave the way for a novel treatment for this common and debilitating condition.”

Notes to Editors